Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is RK Asset Management LLC's 3rd Largest Position

RK Asset Management LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 12,563 shares of the biopharmaceutical company's stock after purchasing an additional 2,574 shares during the period. Regeneron Pharmaceuticals accounts for 7.4% of RK Asset Management LLC's investment portfolio, making the stock its 3rd largest position. RK Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $7,968,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in REGN. Capital International Investors increased its stake in Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after purchasing an additional 155,369 shares during the last quarter. Dodge & Cox raised its stake in Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after purchasing an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Regeneron Pharmaceuticals by 7.9% during the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after purchasing an additional 149,124 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 18.5%

NASDAQ:REGN traded down $112.15 during mid-day trading on Friday, reaching $493.24. 6,307,887 shares of the company's stock traded hands, compared to its average volume of 829,478. The company has a 50 day moving average price of $584.25 and a 200-day moving average price of $667.42. The firm has a market capitalization of $53.25 billion, a price-to-earnings ratio of 12.89, a PEG ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 12-month low of $485.00 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $9.55 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. TD Cowen decreased their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday. Wells Fargo & Company reissued an "equal weight" rating and issued a $580.00 target price (down previously from $700.00) on shares of Regeneron Pharmaceuticals in a research note on Friday. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Finally, Citigroup upgraded Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the company from $600.00 to $700.00 in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $874.56.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.